Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
J Infect Dis ; 219(8): 1178-1186, 2019 04 08.
Article in English | MEDLINE | ID: mdl-30247561

ABSTRACT

BACKGROUND: Oral poliovirus vaccine (OPV) is less immunogenic in low- or middle-income than in high-income countries. We tested whether bacterial and viral components of the intestinal microbiota are associated with this phenomenon. METHODS: We assessed the prevalence of enteropathogens using TaqMan array cards 14 days before and at vaccination in 704 Indian infants (aged 6-11 months) receiving monovalent type 3 OPV (CTRI/2014/05/004588). Nonpolio enterovirus (NPEV) serotypes were identified by means of VP1 sequencing. In 120 infants, the prevaccination bacterial microbiota was characterized using 16S ribosomal RNA sequencing. RESULTS: We detected 56 NPEV serotypes on the day of vaccination. Concurrent NPEVs were associated with a reduction in OPV seroconversion, consistent across species (odds ratio [95% confidence interval], 0.57 [.36-.90], 0.61 [.43-.86], and 0.69 [.41-1.16] for species A, B, and C, respectively). Recently acquired enterovirus infections, detected at vaccination but not 14 days earlier, had a greater interfering effect on monovalent type 3 OPV seroresponse than did persistent infections, with enterovirus detected at both time points (seroconversion in 44 of 127 infants [35%] vs 63 of 129 [49%]; P = .02). The abundance of specific bacterial taxa did not differ significantly according to OPV response, although the microbiota was more diverse in nonresponders at the time of vaccination. CONCLUSION: Enteric viruses have a greater impact on OPV response than the bacterial microbiota, with recent enterovirus infections having a greater inhibitory effect than persistent infections.


Subject(s)
Enterovirus , Gastrointestinal Microbiome , Intestines/virology , Poliovirus Vaccine, Oral/pharmacology , Seroconversion , Enterovirus/genetics , Enterovirus Infections/epidemiology , Enterovirus Infections/immunology , Gastrointestinal Microbiome/genetics , Humans , India/epidemiology , Infant , Intestines/microbiology , Poliovirus Vaccine, Oral/immunology , RNA, Ribosomal, 16S/genetics
2.
Nat Commun ; 12(1): 7288, 2021 12 15.
Article in English | MEDLINE | ID: mdl-34911947

ABSTRACT

Identifying risk factors for impaired oral rotavirus vaccine (ORV) efficacy in low-income countries may lead to improvements in vaccine design and delivery. In this prospective cohort study, we measure maternal rotavirus antibodies, environmental enteric dysfunction (EED), and bacterial gut microbiota development among infants receiving two doses of Rotarix in India (n = 307), Malawi (n = 119), and the UK (n = 60), using standardised methods across cohorts. We observe ORV shedding and seroconversion rates to be significantly lower in Malawi and India than the UK. Maternal rotavirus-specific antibodies in serum and breastmilk are negatively correlated with ORV response in India and Malawi, mediated partly by a reduction in ORV shedding. In the UK, ORV shedding is not inhibited despite comparable maternal antibody levels to the other cohorts. In both India and Malawi, increased microbiota diversity is negatively correlated with ORV immunogenicity, suggesting that high early-life microbial exposure may contribute to impaired vaccine efficacy.


Subject(s)
Gastrointestinal Microbiome , Infant, Newborn, Diseases/prevention & control , Rotavirus Infections/microbiology , Rotavirus Infections/prevention & control , Rotavirus Vaccines/administration & dosage , Rotavirus/immunology , Antibodies, Viral/blood , Antibodies, Viral/immunology , Female , Humans , Immunity, Maternally-Acquired , Immunoglobulin A/blood , Immunoglobulin A/immunology , India , Infant , Infant, Newborn , Infant, Newborn, Diseases/blood , Infant, Newborn, Diseases/microbiology , Infant, Newborn, Diseases/virology , Malawi , Male , Milk, Human/chemistry , Milk, Human/immunology , Pregnancy , Prospective Studies , Rotavirus/genetics , Rotavirus/physiology , Rotavirus Infections/blood , Rotavirus Infections/virology , Rotavirus Vaccines/immunology , United Kingdom , Vaccine Efficacy , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/immunology , Virus Shedding
SELECTION OF CITATIONS
SEARCH DETAIL